ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)

BACKGROUND: Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies patients to guide adjuvant treatment decisions. We are conducting the UK...

Descripción completa

Detalles Bibliográficos
Autores principales: Slater, Susanna, Bryant, Annette, Chen, Hsiang-Chi, Begum, Ruwaida, Rana, Isma, Aresu, Maria, Peckitt, Clare, Zhitkov, Oleg, Lazaro-Alcausi, Retchel, Borja, Victoria, Powell, Rachel, Lowery, David, Hubank, Michael, Rich, Thereasa, Anandappa, Gayathri, Chau, Ian, Starling, Naureen, Cunningham, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026439/
https://www.ncbi.nlm.nih.gov/pubmed/36941575
http://dx.doi.org/10.1186/s12885-023-10699-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026439/
https://www.ncbi.nlm.nih.gov/pubmed/36941575
http://dx.doi.org/10.1186/s12885-023-10699-4

Ejemplares similares